Clinical Trial Update: Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout [Phase 4]

View source ↗

Summary

Phase 4 trial comparing intensive urate lowering with febuxostat vs allopurinol to assess cardiovascular risk in gout patients; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• Allopurinol (Allopurinol)
• FEBUXOSTAT (Febuxostat)

Snippet

Sponsor: Menarini International Operations Luxembourg SA | Conditions: Gout | Phase 4 | Status: COMPLETED | Results posted: 2019-06-21